| Vol. 9.23 – 15 June, 2021 |
| |
|
|
| To aid in understanding tissue-specific pathophysiology, researchers compiled a single-cell transcriptome atlas of human oral mucosa in healthy individuals and patients with periodontitis. [Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that metastatic disease in the pleural and peritoneal cavities was associated with poor clinical outcomes after immune checkpoint blockade therapy. [Cancer Cell] |
|
|
|
| Scientists observed monoamine oxidase A (MAO-A) induction in mouse and human tumor-associated macrophages (TAMs). MAO-A-deficient mice exhibited decreased TAM immunosuppressive functions corresponding with enhanced antitumor immunity. [Nature Communications] |
|
|
|
| Investigators discovered two novel V-domain Ig suppressor of T cell activation (VISTA) antibodies and characterized their effects on human peripheral blood mononuclear cells by scRNA/CITE-seq. [Journal of Experimental Medicine] |
|
|
|
| Researchers found that FOXA1 overexpression inversely correlated with interferon signature and antigen presentation gene expression in prostate cancer and breast cancer patients. [Journal of Clinical Investigation] |
|
|
|
| B cells may serve as a potential biomarker to predict clinical outcome in patients with advanced melanoma treated with dabrafenib plus trametinib. [Clinical Cancer Research] |
|
|
|
| A large cohort of chemotherapy-naïve triple-negative breast cancer (TNBC), clinicopathologic features, deconvoluted RNA immune signatures, and intraepithelial and stromal TIME were identified in subsets of PD-L1+ and PD-L1- TNBC. [Clinical Cancer Research] |
|
|
|
| Scientists used RNA fluorescence in situ hybridization and immunofluorescence to profile epigenetic features of the inactive X at the single-cell level in human B cell subsets from pediatric and adult systemic lupus erythematous patients and healthy controls. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors provided a clinically suitable cell culture platform to generate high numbers of clinically potent nonmodified or genetically modified human T-lymphoid progenitors for accelerating immune recovery after hematopoietic stem cell transplantation and for T-cell-based immunotherapy. [Cellular & Molecular Immunology] |
|
|
|
| Investigators employed a high-dimensional mass cytometry approach to characterize over 250 cell-specific functional responses in 18 innate and adaptive immune cell subsets exposed to 1G or simulated µG using the Rotating Wall Vessel. [Scientific Reports] |
|
|
|
| Researchers tested the hypothesis that a particular immune activation profile might be correlated with insulin resistance in a general population. [Scientific Reports] |
|
|
|
|
| The authors summarize the key findings on TCF1 across the fields of T cell immunity and reflect on the possibility of exploring TCF1 and its downstream transcriptional programmes as therapeutic targets for improving antiviral and antitumour immunity. [Nature Reviews Immunology] |
|
|
|
| Scientists review selected recent advances both in preclinical experimental transplantation and translational human studies, including new insights into human immunology, the microbiome, and regenerative medicine. [Journal of Clinical Investigation] |
|
|
|
| Investigators focus on emerging and novel mechanisms of action of bispecific antibodies interacting with immune cells with at least one of their arms to regulate the activity of the immune system by redirecting and/or reactivating effector cells toward tumor cells. [Clinical Cancer Research] |
|
|
|
|
| ONK Therapeutics Ltd announced that it has been awarded an Innovation Partnership Programme grant by Enterprise Ireland to fund collaborative research at Trinity College Dublin, Ireland, led by Dr. David Finlay to optimize the metabolism and engineering of NK cells for improved cancer therapies. [ONK Therapeutics, Ltd.] |
|
|
|
| 4D pharma plc announced the completion of its target enrollment of 30 patients for Part A of its Phase I/II clinical trial of MRx-4DP0004 in patients with partly-controlled asthma. [4D pharma plc] |
|
|
|
|
| June 28 – 30, 2021 Virtual |
|
|
|
|
|
| Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| University of Bristol- Bristol, England, United Kingdom |
|
|
|
| European School of Molecular Medicine – Milan & Naples, Italy |
|
|
|
| The Wistar Institute – Philadelphia, Pennsylvania, United States |
|
|
|
| Icahn School of Medicine at Mount Sinai – New York City, New York, United States |
|
|
|
|